ArticlePatient preference and adherence2013
Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.
Article in Patient preference and adherence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The association between medication non-adherence and adverse health outcomes in ageing populations: A systematic review and meta-analysis.British journal of clinical pharmacology · 2019Pooled it
- Does Non-Adherence Increase Treatment Costs in Schizophrenia?PharmacoEconomics · 2018Pooled it
- Pooled it
- Trial
- Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China.Schizophrenia research · 2018Trial
- Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.Social psychiatry and psychiatric epidemiology · 2016Trial
- Trial
- Digital and Biomarker-Based Monitoring for Schizophrenia-Treatment Adherence.Neuropsychopharmacology reports · 2026Review
- The global economic burden of schizophrenia: an umbrella review of systematic reviews and meta-analyses with reconstructed primary-study cost data.Health economics review · 2026Review
- Article
- Schizophrenia Treatment Based on Sustained Release of Risperidone from Poly(lactic-ACS applied materials & interfaces · 2025Article
- Article
- Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia.Patient preference and adherence · 2024Article
- Place of care and costs associated with acute episodes and remission in schizophrenia.Journal of managed care & specialty pharmacy · 2023Article
- Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study.Schizophrenia research and treatment · 2023Article
- Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium.BMC psychiatry · 2022Article
- Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics.BMC psychiatry · 2022Article
- Domiciliary tDCS in Geriatric Psychiatric Disorders: Opportunities and Challenges.Indian journal of psychological medicine · 2021Article
- Sociodemographic Factors and Medication Administration Factors Affecting Re - Hospitalization in Patients with Schizophrenia - Spectrum Disorders.The Psychiatric quarterly · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThere is strong evidence supporting the link between nonadherence to antipsychotic medication and relapse of schizophrenia. However, less obvious are the economic consequences of nonadherence. The systematic review reported here evaluated the economic aspects of nonadherence to antipsychotic medication.
methodsA systematic review of scientific papers in the PubMed MEDLINE, Embase, PsychINFO, BIOSIS, and Evidence-Based Medicine Reviews databases was undertaken. Studies that measured adherence to antipsychotic medication and that provided comparative information on health care costs were included.
resultsEight studies met the inclusion criteria. All were observational. Despite the differences between the studies in terms of design, adherence measures, and cost components analyzed, the results of this systematic review indicate that nonadherence to antipsychotic medication is associated with increased hospitalization rates and resource utilization, resulting in increased direct health care costs.
conclusionNonadherence to antipsychotic medication results in poor health and economic outcomes; therefore, the authors suggest endorsing interventions aimed at improving adherence because they can improve patient health without substantially increasing costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.